Xelafaslatide
Based on 1 Customer Validation
Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 2040964-58-5
- Formula: C71H100N18O16
- Molecular Weight:1461.66
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Neuroprotective Compound Library
HY-L070
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Peptide Library
HY-L105
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Pattern Recognition Receptors Library
HY-L237
All Caspase Isoforms
More
Biological Activity
|
IL-6 |
IL-1β |
Caspase 8 |
TLR4 |
NLRP3 |
Xelafaslatide (15-125 μM; 4 h-overnight) dose-dependently blocks FasL-mediated apoptosis of murine A20 B lymphoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine A20 B lymphoma cells
-
Concentration:15 μM, 30 μM, 60 μM, 125 μM
-
Incubation Time:4 h (with mFasL-VP); overnight (with 3H-thymidine)
-
Result:Inhibited mFasL-induced apoptosis of A20 cells in a dose-dependent manner.
Significantly increased cell survival at all tested concentrations relative to vehicle-treated mFasL-VP-exposed cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J wild-type (8-week-old, glaucoma model induced by anterior chamber injection of 15-μm polystyrene microbeads)[1]
-
Dosage:2 μg per 1 μL
-
Administration:intravitreal; single dose (day 0, prior to microbead injection)
-
Result:Achieved RGC density equivalent to saline-injected control mice, fully preventing microbead-induced RGC loss.
Attained optic nerve axon density equivalent to saline-injected control mice, fully preventing microbead-induced axon loss.
Preserved a quiescent, dendritic morphology in Iba1+ retinal microglia (ganglion cell layer/inner plexiform layer), with significantly longer microglial cell processes compared to vehicle-treated microbead-injected mice.
Abrogated the microbead-induced upregulation of multiple inflammatory and glial activation genes (including GFAP, Caspase-8, TNFα, IL-1β, IL-18, IL-6, MIP-1α, MIP-1β, MIP-2, MCP1, IP10, C3, C1Q, TLR4, and NLRP3), with gene expression levels equivalent to saline-injected controls.
Chemical Information
-
CAS No. 2040964-58-5
-
Appearance Solid
-
Molecular Weight 1461.66
-
Formula C71H100N18O16
-
Color White to off-white
-
Synonyms
ONL-1204
-
Sequence
His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2
-
Sequence Shortening
HHIYLGAVNYIY-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (68.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6842 mL | 3.4208 mL | 6.8415 mL | 17.1038 mL |
| 5 mM | 0.1368 mL | 0.6842 mL | 1.3683 mL | 3.4208 mL | |
| 10 mM | 0.0684 mL | 0.3421 mL | 0.6842 mL | 1.7104 mL | |
| 15 mM | 0.0456 mL | 0.2281 mL | 0.4561 mL | 1.1403 mL | |
| 20 mM | 0.0342 mL | 0.1710 mL | 0.3421 mL | 0.8552 mL | |
| 25 mM | 0.0274 mL | 0.1368 mL | 0.2737 mL | 0.6842 mL | |
| 30 mM | 0.0228 mL | 0.1140 mL | 0.2281 mL | 0.5701 mL | |
| 40 mM | 0.0171 mL | 0.0855 mL | 0.1710 mL | 0.4276 mL | |
| 50 mM | 0.0137 mL | 0.0684 mL | 0.1368 mL | 0.3421 mL | |
| 60 mM | 0.0114 mL | 0.0570 mL | 0.1140 mL | 0.2851 mL |
Xelafaslatide Related Classifications
Cat. No.: HY-P10227
Powered by Bioz
- Xelafaslatide
- 2040964-58-5
- ONL-1204
- ONL1204
- ONL 1204
- Fatty Acid Synthase (FASN)
- Apoptosis
- Interleukin Related
- Toll-like Receptor (TLR)
- NOD-like Receptor (NLR)
- Caspase
- retinal ganglion cell
- chemokines
- pro-inflammatory genes
- axon degeneration
- inflammasome pathway mediators
- retinal microglia
- complement cascade components
- Toll-like receptor pathway mediators
- cytokines
- Fas receptor
- Inhibitor
- inhibitor
- inhibit